Given the intricate crosstalk between complement and coagulation systems in driving thrombo-inflammatory injury during stroke, understanding how fibrinolytic agents such as tPA and TNK influence complement activation—particularly C3a generation—offers critical insight into the unintended neurovascular consequences of reperfusion therapy and the potential for targeted complement modulation to mitigate these effects. The gene discussed is C3; the disease is Stroke.